Elan Risks Losing $2 Billion If Royalty Pharma Walks

Elan Risks Losing $2 Billion If Royalty Pharma Walks

Barry Cronin/Bloomberg

Elan Corp. shareholders vote next week on whether to endorse the sale to Royalty Pharma or back Elan Chief Executive Officer Kelly Martin’s strategy of buying drug rights as an independent company.